Document:

Exhibit
4.2

 

Certificate
of Designation of 

Preferences,
Rights and Limitations OF 

SERIES
A PREFERRED STOCK OF 

BOSTON
THERAPEUTICS, INC. 

 

Pursuant
to Section 151 of the Delaware 

General
Corporation Law

 

I,
Carl W. Rausch, Chief Executive Officer of Boston Therapeutics, Inc., a corporation organized and existing under the Delaware
General Corporation Law (the “Corporation”), in accordance with the provisions of Section 151 of such law,
DO HEREBY CERTIFY that at a meeting of the Board of Directors that the following resolutions were adopted:

 

RESOLVED,
that pursuant to the authority vested in the Board of Directors of the Corporation in accordance with the provisions of Article
FOURTH of the Corporation’s Certificate of Incorporation, as amended, a series of Preferred Stock of the Corporation be,
and hereby is, created, and the powers, designations, preferences and relative, participating, optional or other special rights
of the shares of such series, and the qualifications, limitations or restrictions thereof, be, and hereby are, as follows:

 

Section
1. Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A Convertible Preferred
Stock (the “Preferred Stock”) and the number of shares so designated shall be 150,000 (which shall not be subject
to increase without the consent of a majority of the holders of the Preferred Stock (each, a “Holder” and collectively,
the “Holders”)). Each share of Preferred Stock shall have $.001 par value and a stated value equal to $10.00
(as adjusted from time to time in accordance with the terms hereof, the “Stated Value”). Capitalized terms
not otherwise defined herein shall have the meaning given such terms in Section 7 hereof.

 

Section
2. Voting Rights. Except as otherwise provided herein and as otherwise prohibited by law, the Preferred Stock shall have
voting rights on an as converted basis (subject to the limitation set forth in Section 4(a)(ii)).

 

Section
3. Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a
“Liquidation”), the Holders shall be entitled to receive out of the assets of the Corporation, whether such
assets are capital or surplus, for each share of Preferred Stock an amount equal to the Stated Value per share before any distribution
or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to
pay in full such amounts, then the entire assets to be distributed to the Holders shall be distributed among the Holders ratably
in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.
The Corporation shall mail written notice of any such Liquidation, not less than 10 days prior to the payment date stated therein,
to each record Holder.

 

    	1 

     

    

  

Section
4. Conversion.

 

(a)          (i)
Conversions at Option of Holder; Conversion at Option of the Corporation. Subject to the Corporation amending its Certificate
of Incorporation to increase its authorized shares of common stock, each share of Preferred Stock shall be convertible into shares
of Common Stock (subject to the limitations set forth in Section 4(a)(iii)) determined by dividing the Stated Value of such share
by the Set Price, at the option of the Holder, at any time and from time to time from and after the Original Issue Date. Holders
shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A (a
“Notice of Conversion”), to the attention of Chief Financial Officer. Each Notice of Conversion shall specify
the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion
at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion
is to be effected, which date may not be prior to the date the Holder delivers such Notice of Conversion to the Corporation by
facsimile (the “Conversion Date”). If no Conversion Date is specified in a Notice of Conversion, the Conversion
Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. The calculations and entries
set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. In the event the closing
market price is above $0.20 for a period of 10 consecutive Trading Days, then the Corporation may required the Holder convert
the Preferred Stock.

 

(ii)
Beneficial Ownership Limitation. (A) The Corporation shall not effect any conversion of the Preferred Stock, and the Holder
shall not have the right to convert any portion of the Preferred Stock to the extent that after giving effect to such conversion,
the Holder (together with the Holder’s affiliates), as set forth on the applicable Notice of Conversion, would beneficially
own in excess of 4.9% of the number of shares of the Common Stock Outstanding immediately after giving effect to such conversion.
Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. To the extent that the limitation
contained in this Section 4(a)(iii) applies, the determination of whether the Preferred Stock is convertible (in relation to other
securities owned by the Holder together with any affiliates) and of which shares of Preferred Stock is convertible shall be in
the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder’s determination
of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder) and which shares
of the Preferred Stock is convertible, in each case subject to such aggregate percentage limitations. To ensure compliance with
this restriction, the Holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that
such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation
to verify or confirm the accuracy of such determination. For purposes of this Section 4(a)(iii), in determining the number of
outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in the
most recent of the following: (A) the Corporation’s most recent Form 10-Q or Form 10-K, as the case may be, (B) a more recent
public announcement by the Corporation or (C) any other notice by the Corporation or the Corporation’s transfer agent setting
forth the number of shares of Common Stock Outstanding. Upon the written or oral request of the Holder, the Corporation shall
within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In
any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise
of securities of the Corporation, including the Preferred Stock, by the Holder or its affiliates since the date as of which such
number of outstanding shares of Common Stock was reported. This restriction may not be waived.

 

    	2 

     

    

 

(iii)
Limitation on Number of Shares Issuable. Notwithstanding anything herein to the contrary, the Corporation shall not issue
to any Holder any shares of Common Stock, including pursuant to any rights herein, including, without limitation, any conversion
rights or right to issue shares of Common Stock in payment of dividends, to the extent such shares, when added to the number of
shares of Common Stock issued or issuable upon conversion of any shares of Preferred Stock pursuant to Section 4(a)(i) would exceed
19.999% of the Corporation’s outstanding Common Stock immediately prior to the Conversion Date or such greater number of
shares of Common Stock permitted pursuant to the corporate governance rules of the Principal Market that is at the time the principal
trading exchange or market for the Common Stock, based upon share volume, as confirmed in writing by counsel to the Corporation
(the “Maximum Aggregate Share Amount”), unless the Corporation first obtains shareholder approval permitting
such issuances in accordance with the Principal Market rules (“Shareholder Approval”). Each Holder shall be
entitled to a portion of the Maximum Aggregate Share Amount equal to the quotient obtained by dividing (x) such the number of
shares of Preferred Stock initially purchased by such Holder by (y) the aggregate number of shares purchased by all Holders. Such
portions shall be adjusted upward ratably in the event all of the shares of Preferred Stock of any Holder are no longer outstanding.
If at any time the number of shares of Common Stock which could, notwithstanding the limitation set forth herein, be issuable
and sold to all Holders during the following 12 months (assuming all dividends are paid in shares of Common Stock during such
period of determination based upon the VWAP at the time of any such determination) equals or exceeds the Maximum Aggregate Share
Amount, then the Corporation shall, subject to any requirements in the Subscription Agreement to act sooner, obtain the Shareholder
Approval applicable to such issuance as soon as is possible, but in any event not later than the 75th day after the
date in which the Corporation determines (or is notified by any Holder) that the Maximum Aggregate Share Amount could be exceeded
and shall continue to seek to obtain Shareholder Approval every 75 days until such Shareholder Approval is obtained. If the Corporation
shall have failed to obtain the Shareholder Approval on or prior to the initial 75th day after the date in which the
Corporation determines (or is notified by a Holder) that the Maximum Aggregate Share Amount would be exceeded, then the dividend
on the Preferred Stock shall thereafter be 15% per annum until such Shareholder Approval is obtained.

 

    	3 

     

    

 

(b)         (i)
Not later than three Trading Days after each Conversion Date (the “Share Delivery Date”), the Corporation shall
deliver to the Holder a certificate or certificates which, after the Effective Date, shall be free of restrictive legends and
trading restrictions representing the number of shares of Common Stock being acquired upon the conversion of shares of Preferred
Stock. If the number of shares of Preferred Stock represented by the Preferred Stock certificate(s) submitted for conversion is
greater than the number of shares of Preferred Stock being converted, then the Corporation shall, as soon as practicable and in
no event later than three (3) business days after receipt of the Preferred Stock certificate(s) and at the Corporation’s
expense, issue and deliver to the holder a new Preferred Stock Certificate representing the number of shares of Preferred Stock
not converted. After the Effective Date, the Corporation shall, upon request of the Holder, deliver any certificate or certificates
required to be delivered by the Corporation under this Section electronically through the Depository Trust Corporation or another
established clearing corporation performing similar functions. Nothing herein shall limit a Holder’s right to pursue injunctive
relief and/or actual damages for the Corporation’s failure to issue and deliver Common Stock to the Holder, including, without
limitation, the Holder’s actual losses occasioned by any “buy-in” of common stock necessitated by such late
delivery. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that the Corporation
fails for any reason to effect delivery of such shares of Common Stock by the Share Delivery Date, the Holder will be entitled
to revoke the relevant Notice of Conversion by delivering a notice to such effect to the Corporation whereupon the Corporation
and the Holder shall each be restored to their respective positions immediately prior to delivery of such Notice of Conversion
except that holder shall retain the right to receive the actual documented cost of any “buy-in.” As used herein, “buy-in”
shall mean the purchase by a holder of Preferred Stock of shares of common stock in an open market transaction or otherwise in
order to meet its delivery obligations in connection with the sale of common stock, which delivery obligation the holder intended
to satisfy with the shares of common stock upon conversion.

 

(c)          (i)
The conversion price for each share of Preferred Stock shall equal $0.10 (the “Set Price”), subject to adjustment
below.

 

    	4 

     

    

 

      (ii)
          if the Corporation, at any time while the Preferred Stock is outstanding:
(A) subdivide outstanding shares of Common Stock into a larger number of shares, (B) combine (including by way of reverse stock
split) outstanding shares of Common Stock into a smaller number of shares, or (V) issue by reclassification of shares of the Common
Stock any shares of capital stock of the Corporation, then the Set Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event and of which the
denominator shall be the number of shares of Common Stock Outstanding after such event. Any adjustment made pursuant to this Section
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

 

(iii)          All
calculations under this Section 4(c) shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account
of the Corporation, and the disposition of any such shares shall be considered an issue or sale of Common Stock. For purposes
of this Section 4(c), the number of shares of Common Stock deemed to be outstanding (the “Common Stock Outstanding”)
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(iv)          Notwithstanding
anything to the contrary herein, no adjustment shall be made hereunder in connection with an Excepted Issuance.

 

(v)          Whenever
the Set Price is adjusted pursuant to this Section the Corporation shall promptly mail to each Holder, a notice setting forth
the Set Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

 

Section
6. Definitions. For the purposes hereof, the following terms shall have the following meanings:

 

“Closing”
means closing of the purchase and sale of the Preferred Stock.

 

“Closing
Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Holders’ obligations to pay the Subscription Amount and (ii) the
Corporation’s obligations to deliver the shares of Preferred Stock and Warrants have been satisfied or waived.

 

“Commission”
means the Securities and Exchange Commission.

 

    	5 

     

    

 

“Common
Stock” means the Corporation’s common stock, $.001 par value per share, and stock of any other class into which
such shares may hereafter have been reclassified or changed.

 

“Common
Stock Outstanding” shall have the meaning set forth in Section 4(c)(vi).

 

“Conversion
Date” shall have the meaning set forth in Section 4(a)(i).

 

“Conversion
Shares” means, collectively, the shares of Common Stock into which the shares of Preferred Stock are convertible in
accordance with the terms hereof.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Holder”
shall have the meaning given such term in Section 1 hereof.

 

“Junior
Securities” means the Common Stock and all other equity or equity equivalent securities of the Corporation other than
those securities that are (a) outstanding on the Original Issue Date and (b) which are explicitly senior in rights or liquidation
preference to the Preferred Stock.

 

“Liquidation”
shall have the meaning given such term in Section 3.

 

“Notice
of Conversion” shall have the meaning given such term in Section 5(a).

 

“Original
Issue Date” shall mean the date of the first issuance of any shares of the Preferred Stock regardless of the number
of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence
such Preferred Stock.

 

“Person”
means a corporation, an association, a partnership, an organization, a business, an individual, a government or political subdivision
thereof or a governmental agency.

 

“Principal
Market” initially means the OTCQB and shall also include the NASDAQ Small-Cap Market, the New York Stock Exchange, or
the NASDAQ National Market, whichever is at the time the principal trading exchange or market for the Common Stock, based upon
share volume.

 

“Purchase
Agreement” means the Securities Purchase Agreement, dated as of the date hereof, to which the Corporation and the original
Holders are parties, as amended, modified or supplemented from time to time in accordance with its terms.

 

    	6 

     

    

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Set
Price” shall have the meaning set forth in Section 4(c)(i).

 

“Stated Value” shall have the meaning given such term in Section 1.

 

“Subscription
Amount” shall mean, as to each Purchaser, the amount to be paid for the Preferred Stock purchased pursuant to the Purchase
Agreement as specified below such Purchaser’s name on the signature page of the Purchase Agreement and next to the heading
“Subscription Amount”, in United States Dollars and in immediately available funds.

 

“Trading
Day” shall mean any day during which the Principal Market shall be open for business.

 

“Transaction
Documents” shall mean the Purchase Agreement and all agreements entered into in connection therewith.

 

Section
7. Miscellaneous.

 

(a)          All
questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting
in the City of New York, Borough of Manhattan (the “New York Courts”). Each party hereto hereby irrevocably submits
to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, or such New York Courts are improper or inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to
limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Certificate of Designation or the transactions contemplated hereby. If either party shall commence an action or proceeding
to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be
reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.

 

    	7 

     

    

 

(b)          Any
waiver by the Corporation or the Holder of a breach of any provision of this Certificate of Designation shall not operate as or
be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate
of Designation. The failure of the Corporation or the Holder to insist upon strict adherence to any term of this Certificate of
Designation on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist
upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver must be in writing.

 

(c)          If
any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable
to all other persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
applicable laws governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
permitted rate of interest.

 

(d)         Whenever
any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next
succeeding Business Day.

 

(e)          The
headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not
be deemed to limit or affect any of the provisions hereof.

 

(f)          RESOLVED,
FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation
be and they hereby are authorized and directed to prepare and file a Certificate of Designation of Preferences, Rights and Limitations
in accordance with the foregoing resolution and the provisions of Delaware law.

 

IN
WITNESS WHEREOF, the undersigned have executed this Certificate this 14th day of August 2017.

 

/s/Carl
W. Rausch

Name:
Carl W. Rausch

Title:
CEO 

 

    	8 

     

    

 

ANNEX
A

 

NOTICE
OF CONVERSION

 

(To
be Executed by the Registered Holder in order to convert shares of Preferred Stock)

 

The
undersigned hereby elects to convert the number of shares of Convertible Preferred Stock indicated below, into shares of common
stock, no par value per share (the “Common Stock”), of Boston Therapeutics, Inc., a Delaware corporation (the
“Corporation”), according to the conditions hereof, as of the date written below. If shares are to be issued
in the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is
delivering herewith such certificates and opinions as reasonably requested by the Corporation in accordance therewith. No fee
will be charged to the Holder for any conversion, except for such transfer taxes, if any.

 

Conversion
calculations:

  

	 	Date to Effect Conversion
	 	 	 
	 	Number of shares of Preferred Stock
    owned prior to Conversion
	 	 	 
	 	Number of shares of Preferred Stock
    to be Converted
	 	 	 
	 	Stated Value of shares of Preferred
    Stock to be Converted
	 	 	 
	 	Number of shares of Common Stock
    to be Issued
	 	 	 
	 	Applicable Set Price
	 	 	 
	 	Number of shares of Preferred Stock
    subsequent to Conversion
	 	 	 

  

	 	[HOLDER]
	 	 	 
	 	By:	 	 
	 	 	Name:
	 	 	Title:

  

    9Exhibit 4.3

 

NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

To Purchase [*] Shares of Common Stock of

 

BOSTON
THERAPEUTICS, INC.

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*]
(the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior
to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”)
but not thereafter, to subscribe for and purchase from Boston Therapeutics, Inc., a Delaware corporation (the “Company”),
up to [*] shares (the “Warrant Shares”) of Common Stock, $.001 par value per share, of the Company (the “Common
Stock”) subject to the Company amending its Certificate of Incorporation increasing its authorized shares of Common
Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). In the event the closing market price is above $0.30 for a period of 10 consecutive Trading Days (the “Trading
Event”), then the Termination Date shall be the 60th day following receipt of notice of the Trading Event by
the Holder from the Company.

 

     Section 1.          Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the “Purchase Agreement”), dated _____ ___, 2017, among the Company and the purchasers signatory
thereto.

 

    1

     

    

 

     Section
2.         Exercise.

 

  a)          Exercise
of Warrant. Subject to the Company amending its Certificate of Incorporation to increase its authorized shares of common stock,
exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy of
the Notice of Exercise Form annexed hereto (or such other office or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of such Holder appearing on the books of the Company).

 

  b)      
   Exercise Price. The exercise price of the Common Stock under this Warrant shall be $0.15,
subject to adjustment hereunder (the “Exercise Price”). Within 5 Trading Days of the date said Notice of
Exercise is delivered to the Company, the Holder shall have surrendered this Warrant to the Company and the Company shall
have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s
check drawn on a United States bank

 

  c)          Exercise Limitations; Holder’s Restrictions. The Holder shall not be entitled to exercise on a Conversion
Date that number of shares of Common Stock which would be in excess of the sum of (i) the number of shares of common stock beneficially
owned by the Holder and any Person, as such term is used in and construed under Rule 144 under the Securities Act, that, directly
or indirectly through one or more intermediaries, controls or is controlled by or is under common control with the Holder (collectively,
“Affiliates”) immediately prior to an exercise, and (ii) the number of shares of Common Stock issuable upon the exercise
of this Warrant with respect to which the determination of this provision is being made, which would result in beneficial ownership
by the Holder and its Affiliates of more than 4.99% of the outstanding shares of Common Stock of the Corporation immediately following
a exercise. For the purposes of the provision to the immediately preceding sentence, beneficial ownership shall be determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. Subject to the
foregoing, the Holder shall not be limited to aggregate exercises of only 4.99% and aggregate exercises by the Holder may exceed
4.99% as the Holder may void the exercise limitation described in this warrant upon and effective after 61 days prior written notice
to the Corporation. The Holder may allocate which of the equity of the Corporation deemed beneficially owned by the Holder shall
be included in the 4.99% amount described above and which shall be allocated to the excess above 4.99%

 

  d)          Mechanics of Exercise.

 

i.         
Authorization of Warrant Shares. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly
authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue and liens imposed upon such shares
as a result of Holder’s actions).

 

    2

     

    

 

ii.         
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the transfer
agent of the Company to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within
3 Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant and payment of the aggregate
Exercise Price as set forth above (“Warrant Share Delivery Date”). This Warrant shall be deemed to have been
exercised on the date the Exercise Price is received by the Company. The Warrant Shares shall be deemed to have been issued, and
Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for
all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all taxes required
to be paid by the Holder, if any, pursuant to Section 2(e)(vii) prior to the issuance of such shares, have been paid.

 

iii.         
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing
the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

iv.         
Rescission Rights. If the Company fails to cause its transfer agent to transmit to the Holder a certificate or certificates
representing the Warrant Shares pursuant to this Section 2(e)(iv) by the Warrant Share Delivery Date, then the Holder will have
the right to rescind such exercise.

 

v.         
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise,
the Company shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price.

 

vi.         
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder
for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and
expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto.

 

    3

     

    

 

vii.         
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

     Section
3.         Certain Adjustments.

 

  a)           Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (A) subdivides outstanding shares
of Common Stock into a larger number of shares, (B) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (C) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted. Any adjustment made pursuant to
this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a
subdivision, combination or re-classification.

 

  b)          Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

  c)           Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant reduce the then current
Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.

 

  d)         
Notice to Holders.

 

i.         
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to this Section 3, the Company shall
promptly mail to each Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment. If the Company issues a variable rate security, despite the prohibition thereon in the
Purchase Agreement, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible
conversion or exercise price at which such securities may be converted or exercised in the case of a Variable Rate Transaction
(as defined in the Purchase Agreement).

 

    4

     

    

 

     Section 4.         Transfer
of Warrant.

 

  a)          Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Sections
5(a) and 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

  b)         
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice.

 

  c)         
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

  d)         
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer
of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under
the Securities Act and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing
such transfer (i) that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of
counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities Act and under applicable state securities
or blue sky laws, (ii) that the holder or transferee execute and deliver to the Company an investment letter in form and substance
acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified institutional buyer as defined in Rule 144A(a) under
the Securities Act.

 

    5

     

    

 

     Section 5.          Miscellaneous.

 

  a)         
Title to Warrant. Prior to the Termination Date and subject to compliance with applicable laws and Section 4 of this
Warrant, this Warrant and all rights hereunder are transferable, in whole or in part, at the office or agency of the Company by
the Holder in person or by duly authorized attorney, upon surrender of this Warrant together with the Assignment Form annexed hereto
properly endorsed. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company.

 

  b)         
No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a shareholder of the Company prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate
Exercise Price (or by means of a cashless exercise), the Warrant Shares so purchased shall be and be deemed to be issued to such
Holder as the record owner of such shares as of the close of business on the later of the date of such surrender or payment.

 

  c)         
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

  d)         
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall be a Saturday, Sunday or a legal holiday, then such action may be taken or such right
may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday.

 

  e)         
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.

 

  f)          
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, will have restrictions upon resale imposed by state and federal securities laws.

 

  g)         
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
of its rights, powers or remedies hereunder.

 

    6

     

    

 

  h)         
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

  i)            Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this
Warrant or purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

  j)            Remedies.
Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to
specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive the defense in
any action for specific performance that a remedy at law would be adequate.

 

  k)         
 Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the
successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders
from time to time of this Warrant and shall be enforceable by any such Holder or holder of Warrant Shares.

 

  l)            Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder.

 

  m)          Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

  n)          Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

    7

     

    

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized.

 

Dated: ___________ ___, 2017

	 	 	 
	 	BOSTON THERAPEUTICS, INC.
	 	 	 
	 	By:	
	 		Name:
	 		Title:

 

    8

     

    

 

NOTICE OF EXERCISE

 

To: BOSTON
THERAPEUTICS, INC.

 

(1) 
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2) 
Payment shall take the form of (check applicable box):

 

[   ] in lawful
money of the United States; or

 

(3) 
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other
name as is specified below:

 

_______________________________

 

The Warrant Shares shall be delivered to
the following:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor.
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity:	 

	Signature of Authorized Signatory of Investing Entity:	 

	Name of Authorized Signatory:	 

	Title of Authorized Signatory:	 

	Date:	 

 

    

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

Dated: ______________,
_______

 

	Holder’s
    Signature:	 	 
	 	 	 
	Holder’s Address:	 	 
	 	 	 
	 	 	 

 

Signature Guaranteed: ___________________________________________

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]